Status:
UNKNOWN
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
Lead Sponsor:
Samsung Medical Center
Conditions:
HER2-positive Breast Cancer
Chemotherapy Effect
Eligibility:
FEMALE
20+ years
Brief Summary
Locally advanced breast cancer (LABC) is defined as breast cancer (BC) larger than 5 centimeters or with lymph node metastasis. Usually, LABC is treated with neoadjuvant chemotherapy (NAC) followed by...
Eligibility Criteria
Inclusion
- HER2+ Breast cancer
- Stage IIA - IIIC
- Plan to receive neoadjuvant chemotherapy with docetaxel, carboplatin, herceptin, perjeta
- Sign to informed consent
Exclusion
- Double primary cancer
Key Trial Info
Start Date :
March 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 31 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04276337
Start Date
March 1 2018
End Date
August 31 2023
Last Update
February 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710